PAVmed (PAVM) Liabilities and Shareholders Equity (2015 - 2025)

PAVmed's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $38.8 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 26.59% year-over-year to $38.8 million in Q4 2025; TTM through Dec 2025 was $173.6 million, a 31.14% increase from a year earlier, with the FY2025 full-year figure at $38.8 million, up 26.59% from the prior year.
• Liabilities and Shareholders Equity climbed to $38.8 million in Q4 2025 per PAVM's latest filing, from $38.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $87.0 million in Q4 2021 and bottomed at $25.0 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $45.6 million (2021), against an average of $51.1 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 433.34% in 2021 and sank 42.94% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $87.0 million in 2021, then sank by 37.94% to $54.0 million in 2022, then plunged by 38.65% to $33.1 million in 2023, then retreated by 7.42% to $30.7 million in 2024, then grew by 26.59% to $38.8 million in 2025.
• Per Business Quant, the three latest PAVM Liabilities and Shareholders Equity figures stand at $38.8 million (Q4 2025), $38.1 million (Q3 2025), and $43.9 million (Q2 2025).